Iron Mountain Inc. (IRM) stock reached a new 52-week high of $115.31, reflecting a 42% total return over the past year and 38% year-to-date gains. Despite this milestone, InvestingPro analysis suggests the stock is currently overvalued. The company recently reported strong Q4 2025 earnings with increased revenue and EPS, leading several analysts to reiterate Buy ratings and raise price targets.

Alphabet Inc. Class C shares saw a slight dip to $333.97 ahead of its Q1 2026 earnings report, as investors weigh recent gains against the company's aggressive capital expenditures in AI infrastructure. Analysts expect strong revenue and profit for the quarter, driven by Google's advertising, YouTube, and Google Cloud, but the significant AI spending of $175-$185 billion for the year raises questions about near-term margin pressure. The company aims for long-term AI dominance, with regulatory risks and evolving competition in search advertising also influencing investor sentiment.

CIBC CEO Harry Culham announced the bank will significantly increase lending to Canadian businesses, particularly in sectors deemed critical by the government for nation-building, such as energy, agriculture, and infrastructure. This move aligns with Ottawa's efforts to encourage more bank lending for major projects and to support small and medium-sized businesses. The bank also plans to expand its capacity in Canada's Northern region to capitalize on critical minerals and resources, while also monitoring the upcoming USMCA renewal negotiations.

Thermo Fisher Scientific has launched the Applied Biosystems™ PowerFlex™ Thermal Cycler, a new PCR instrument designed to enhance flexibility, thermal performance, and productivity in molecular biology laboratories. This next-generation system aims to address the challenges of complex PCR workflows with fast and precise results, intuitive operation via a 10.1-inch touchscreen, and flexible configurations including a 3x32-well model for simultaneous independent experiments. The PowerFlex Thermal Cycler supports a wide range of applications from life science research to human identification.

HCA Healthcare announced that 29 of its hospitals have been recognized on Modern Healthcare’s 2026 "100 Top Hospitals Powered by Premier" list. Seven of these hospitals also received the Everest Award for sustained improvement. The recognition is based on objective analysis of clinical outcomes, operational efficiency, patient experience, and financial health, highlighting HCA Healthcare's commitment to advancing clinical excellence and patient care.

Belden Inc. will report its fiscal first quarter results for the period ended March 29, 2026, before market open on Thursday, April 30, 2026. Management will discuss the results during a conference call at 8:30 a.m. Eastern Time, with a webcast available on the company's investor relations website. Investors can access the live broadcast online or participate via teleconference.

Amaze (NYSE American: AMZE) launched its Food Channel on April 16, 2026, activating the distribution layer of its creator-commerce platform. This model integrates creator-led content, commerce conversion, and partner distribution, notably accessing the Los Angeles Times network of over 47 million monthly users, to generate near-term revenue. Amaze plans to expand this strategy across Music, Gaming, Health, and Lifestyle verticals, aiming to convert content engagement into repeatable transactions within the growing creator economy.

UiPath has launched two new offerings on Salesforce's AgentExchange: UiPath CX Companion and UiPath Maestro Connector. These tools integrate AI-powered automation and orchestration into agent-driven workflows across Salesforce and other enterprise systems. The aim is to eliminate friction, manual processes, and disconnected data, allowing teams to focus on outcomes.

Aspire Biopharma (NASDAQ:ASBP), a biopharmaceutical company, has signed a Letter of Intent to acquire Dura Driver Control Systems (DCS), a global automotive supplier, for $30 million in cash. DCS reported over $200 million in revenue and $20 million in adjusted EBITDA for FY2025 (unaudited), marking a significant diversification for Aspire Biopharma from its biotech focus into the automotive industry. The acquisition is subject to due diligence and a U.S. GAAP audit, and if completed, will bolster DCS's management with experienced automotive leadership.

Prologis ($PLD) reported its Q1 2026 earnings, with earnings per share of $1.50, surpassing estimates of $0.82. However, the company missed revenue estimates, reporting $2.125 billion against an expectation of $2.234 billion. The article also details recent insider, hedge fund, and congressional trading activity, along with analyst ratings and price targets for PLD.